• Tepotinib (also known as MSC2156119J) is an investigational small molecule inhibitor of the MET receptor tyrosine kinase
• Alterations in the MET signaling pathway are found in various cancer types and appear to correlate with aggressive tumor behavior and poor clinical prognosis